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To mimic natural extracellular matrix architecture, tetrandrine-loaded poly(L-lactic acid) 
scaffolds modified by gelatin were prepared via phase separation, solvent replacement and 
freeze-drying. The purpose of this work was to combine the biological effects of tetrandrine and 
the advantages of poly(L-lactic acid) scaffolds which was modified by gelatin to enhancing the 
mass transfer features of controlled release systems. Tetrandrine contained in the scaffolds was 
confirmed by X-ray photoelectron spectroscopy (XPS) and Fourier-transform infrared (FT-IR) 
spectroscopy. Tetrandrine did not change the morphous, crystallinity and thermodynamics of 
the scaffolds which demonstrated by differential scanning calorimetry (DSC), scanning electron 
microscopy (SEM) and X-ray powder diffractometry (XRD). The results of this study showed a 
sustained release with 79.15% for 188 days in vitro.
Keywords: poly(lactic acid) scaffolds, gelatin, tetrandrine, tissue engineering.
С целью воссоздания естественной архитектуры внутриклеточного матрикса  методами 
разделения фаз, заменой растворителя и сублимационной сушки были синтезированы 
полимерные каркасы поли(L-молочной кислоты), модифицированные желатином и 
загруженные тетрандрином. Цель данной работы состояла в объединении биологического 
эффекта тетрандрина и преимуществ синтезированных каркасов для повышения 
характеристик массопереноса с контролируемым высвобождением лекарственного вещества 
(тетрандрина). Присутствие тетрандрина в синтезированных каркасах определялось 
методами рентгеновской фотоэлектронной спектроскопии и инфракрасной спектроскопии 
с Фурье-преобразованием. Методами дифференциально сканирующей калориметрии, 
сканирующей электронной микроскопии и рентгенфазового анализа показано, что 
тетрандрин не изменяет морфологию, кристалличность и термодинамику образования 
каркасов. Результаты исследования in vitro показали, что синтезированные каркасы 
обеспечивают пролонгированное высвобождение 79,15% тетрандрина в течение 188 дней. 
Полімерні каркаси полі (L-молочної кислоти), модифіковані желатином для 
контрольованого вивільнення тетрандріна in vitro. Zhang Ye
З метою відтворення природної архітектури внутрішньоклітинного матриксу  методами 
розподілу фаз, заміною розчинника та сублімаційною сушкою були синтезовані полімерні 
каркаси полі (L-молочної кислоти), модифіковані желатином і завантажені тетрандріном. 
Мета даної роботи полягала в об’єднанні біологічного ефекту тетрандріна і переваг 
синтезованих каркасів для підвищення характеристик масопереносу з контрольованим 
вивільненням лікарської речовини (тетрандріна). Присутність тетрандріна в синтезованих 
каркасах визначався методами рентгенівської фотоелектронної спектроскопії та 
інфрачервоної спектроскопії з Фур’є-перетворенням. Методами диференційно скануючої 
калориметрії, скануючої електронної мікроскопії та рентген-фазового аналізу показано, 
що тетрандрін не змінює морфологію, кристалічність і термодинаміку створення каркасів. 
Результати дослідження in vitro показали, що синтезовані каркаси забезпечують 
пролонговане вивільнення 79,15% тетрандріна протягом 188 днів.
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1. Introduction
Much interest has been generated recently 
in the area of tissue engineering to create bio-
logical alternatives for implants and prosthe-
ses. In this approach, a highly porous scaffold 
(artifical extracellular matrix) is needed to ac-
commodate cells and guide their growth and 
tissue regeneration in three dimensions. Biode-
gradable polymers, either natural or synthetic, 
have been processes into scaffolds for tissue en-
gineering [14]. Poly(lactic acid) (PLLA), a biode-
gradable synthetic materials, was widely used 
in biomedical engineering due to their innocu-
ity, biodegradability, bioenvironmental com-
patibility and so on [14, 25, 6]. It was therefore 
approved by the Food and Drug Administration 
(FDA) for certain human clinical applications 
such as surgical sutures and some implantable 
devices. Recently, porous PLLA scaffolds were 
widely investigated in osteoblastic [32], cranial 
bone [22] , corneal [1], chondrocyte [2] tissue 
engineering, etc. However, one disadvantage of 
PLLA scaffold was the complications resulting 
from the accumulation of lactic acid produced 
in the process of degradation.  
Growth factor is mostly water soluble pro-
tein from human or animal. Its price is expen-
sive, and its biological property is unstable. 
Thus, its loading on the scaffolds has certain 
difficulty. Additionally, excessive dose of growth 
factor may induce tumor cell growth. Antibiot-
ics are also used in engineering scaffolds for 
antibacterial and anti-infection in vitro [12]. 
However, the pharmacological action of anti-
biotics is only simple antibacterial. Antibiotics 
have no physiological activity. Some effective 
components in traditional Chinese medicine 
has a function similar to that of the cytokines 
and the corresponding pharmacological effects, 
and the price is low, the physical and chemical 
properties is relative stability. Thus, they show 
good prospects for application as substitutes of 
cytokines. Tetrandrine (Tet), a bis-benzyliso-
quinoline alkaloid isolated from the dried root 
of the natural Chinese herb Stephania tetran-
dra which used as an effective agent for rheu-
matic arthritis and rheumatoid arthritis exhib-
its a variety of pharmacological activities such 
as anti-inflammatory, antioxidant, anti-fibrotic 
and anticancer activities, antiplatelet aggrega-
tion, Ca2+ channel block, immunosuppressive, 
and free radical scavenging effects [11, 13, 17, 
23, 24, 30]. Consequently, it has effective func-
tion in the treatment of many diseases includ-
ing pulmonary diseases, hepatic fibrosis, ar-
thritis, silicosis and so on [9,10,16, 20]. Tet has 
also shown antidepressant-like effect by regu-
lating the central monoaminergic neurotrans-
mitter system and the levels of BDNF [7] . Ac-
cording to previous literature, low concentra-
tion of Tet (1-2.5 mg/L) promotes proliferation, 
activity and glycosaminoglycan and collagen-
secreting of chondrocyte. Thus, Tet has great 
prospective future in cartilaginous tissue en-
gineering applications [5]. Compared with con-
trol PLLA films, Tet loaded in the poly (L-lactic 
acid) (PLLA) films could reduce the inflamma-
tory response in macrophages by regulating 
the mRNA expression and protein expression, 
and significantly inhibit inflammatory reaction 
in 4, 12 weeks after implanting in rats. There-
fore, Tet could enhanced the biocompatibility of 
PLLA films [21].
The purpose of the present work was to pre-
pare Tet-loaded PLLA scaffolds modified by 
gelatin and investigate the controlled release 
of tetrandrine in vitro. PLLA scaffolds modi-
fied by gelatin, as biomimetic surface modifier 
could elicit controlled cellular adhesion and 
maintain differentiated phenotypic expres-
sion [4], were prepared via phase separation, 
solvent replacement, freeze-drying. Then, Tet 
which presents anti-inflammatory activities 
and physiological activities similar to cytokine 
was loaded on PLLA scaffolds modified. Alka-
lescence and anti-inflammatory activities of 
Tet could relieve complications resulting from 
the accumulation of lactic acid produced in the 
process of degradation. The drug with specific 
properties could be sustained delivered to the 
necessary site of action, and thus repair recon-
stituted cartilage tissue and maintain its phe-
notype and cellular function. X-ray photoelec-
tron spectroscopy (XPS) and Fourier-transform 
infrared (FT-IR) spectroscopy were measured 
to evaluate the formulation of modified PLLA 
scaffolds and Tet-loaded PLLA scaffolds. Dif-
ferential scanning calorimetry (DSC), scanning 
electron microscopy (SEM) and X-ray powder 
diffractometry (XRD) were performed to com-
pare the physicochemical properties. On the 
other hand, drug content and release behaviors 
were performed to evaluate sustained release 
characteristics of Tet-loaded PLLA scaffolds.
2. Materials and methods
2.1 Materials
Poly(L-lactic acid) (PLLA, Mn=4.32×104 g/mol) 
was kindly donated by Prof. Xue-Si Chen, 
Changchun Institute of Applied Chemistry 
Chinese Academy of Sciences. Tetrandrine 
(Tet) and gelatin were purchased from Sigma-
Aldrich Co. (St Louis, USA). HPLC grade aceto-
nitrile were supplied by Merck & Co., Inc. (Bei-
jing, China). Other materials and solvents used 
were of analytical reagent grade.
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2.2 Preparation of PLLA scaffolds
On the basis of the theory of thermally in-
duced phase separation (TIPS) and freeze-dry-
ing approach (FDA) [15,18,29,31], three-dimen-
sional microporous PLLA scaffolds modified 
by gelatin were fabricated via phase separa-
tion, solvent replacement and freeze-drying. A 
typical procedure was used as following: pre-
weighed PLLA was dissolved in tetrahydrofu-
ran (THF) at 60°C to form 5% (wt/v, polymer/
THF) solution. The solution was poured into 
glass vials, which were then quickly put into 
-80°C refrigerator for 24 hours to gel. The vials 
containing the PLLA solution was then trans-
ferred into 50% (v/v) ethanol at -20°C. After 24 
hours for solvent exchange, the ethanol was re-
placed with 5 wt % gelatin aqueous solution for 
16 hours at room temperature. Then, the gel 
was placed in distilled water for 2 day, exchang-
ing with fresh distilled water three times a day, 
and then put into -20°C refrigerator again for 
freezing. Afterwards, the frozen gel lyophilized 
in a freeze-drier for the purpose of removing 
water sufficiently and the PLLA scaffolds were 
acquired accordingly.
The fabrication of Tet-loaded PLLA scaf-
folds was slightly different from that of PLLA 
scaffolds. One needs to add 10% Tet (wt/wt, 
Tet/polymer) in 5% (wt/v, polymer/THF) poly-
mer solution before pouring into glass vials. All 
other processes were identical.
2.3 Characterization of PLLA scaffolds
XPS measurements of PLLA scaffolds, 
modified PLLA scaffolds and Tet-loaded PLLA 
scaffolds were performed on a instrument (Per-
kin Elmer 5600, USA) with Al Kα radiation 
(hv=1486.6 eV). The values of binding energies 
were calibrated with respect to C1s peak at 
284.7 eV.
FT-IR spectra of PLLA scaffolds modified 
PLLA scaffolds and Tet-loaded PLLA scaffolds 
were recorded on an infrared spectrometer 
(BIO-RAD FTS3000, USA). The samples were 
prepared by the potassium bromide disc meth-
od and scanned for absorbance 4000-400 cm−1.
The powder X-ray diffraction patterns of 
modified PLLA scaffolds and Tet-loaded PLLA 
scaffolds were recorded using an X-ray diffrac-
tometer (Rigaku D/max-2500, Japan). Radia-
tions generated from Cu Kα source and filtered 
through Ni filters with a wavelength of 0.154 
nm at 20 mA and 36 kV were used. The scan-
ning rate employed was 4°/min over the 10-40° 
range.
DSC thermograms of scaffolds were record-
ed on a differential scanning calorimeter (PER-
KIN-ELMER DSC 7, USA). The instrument 
was calibrated with indium and zinc prior to 
analyzing the samples under nitrogen. All ac-
curately weighed samples (2.5 mg) were placed 
into sealed aluminium pans and scanned at the 
heating rate of 10 °C/min over the temperature 
range of 30-250 °C.
Scaffolds were viewed with a scanning elec-
tron microscope (SEM, Philips XL30, Nether-
lands). The surface and inner microstructures 
were investigated on specimen surfaces and 
cross-sections cut in liquid nitrogen. The sam-
ples were coated with gold prior to SEM obser-
vation.
2.4 Determination of Tet release behaviors
Pre weighed amounts of PLLA scaffolds were 
suspended in 50 mL of PBS (pH 7.4) buffer solu-
tion at 37°C. At predetermined time intervals, 
200 μL of released solution was withdrawn for 
measuring, which was replenished by 200 μL 
of fresh PBS solution to maintain a constant 
volume. The concentration of released Tet was 
monitored on a Waters 2695 series HPLC sys-
tem. 20-microliter samples were injected on a 
reversed-phase HPLC column (Thermo C18, 
250 mm´4.6 mm, 5 μm). The mobile phase con-
sisted of a mixture of acetonitrile and water at 
30:70 containing 0.12% (v/v) diethylamine and 
pH value was modified at 4 by phosphoric acid 
(H3PO4). Flow rate was adjusted to 1.0 mL/min. 
All samples were analyzed in triplicate at 282 
nm. The average and standard deviations were 
presented. 
3. Results and discussion
3.1 XPS
XPS is a quantitative spectroscopic tech-
nique that measures the elemental composi-
tion, empirical formula, chemical state and 
electronic state of the elements that exist with-
in a material. XPS spectra are obtained by irra-
diating a material with a beam of X-rays while 
simultaneously measuring the kinetic energy 
(KE) and number of electrons that escape from 
the top 1 to 10 nm of the material being ana-
lyzed. A typical XPS spectrum is a plot of the 
number of electrons detected (sometimes per 
unit time) (Y-axis, ordinate) versus the binding 
energy of the electrons detected (X-axis, abscis-
sa). Each element produces a characteristic set 
of XPS peaks at characteristic binding energy 
values that directly identify each element that 
exist in or on the surface of the material being 
analyzed.
The XPS spectrum of scaffolds was shown in 
Figure 1. As can be discovered, PLLA scaffolds 
showed two XPS peaks at 284.7 eV and 532.8 
eV which assigned to C1s and O1s respectively. 
By contrast, modified PLLA scaffolds displayed 
a new XPS peaks at 399.5 eV which attributed 
to N1s due to cyano (-CONH) or amine (-NH2 ) 
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groups of gelatin. Therefore, gelatin was con-
tained on the surface of PLLA scaffolds. As ex-
pected, the surface nitrogen content is larger for 
Tet-loaded PLLA scaffolds, compared to PLLA 
scaffolds modified by gelatin (Table 1). This 
result can be attributed to nitrogen of tertiary 
amines contained in Tet. In this case, Tet was 
contained on the surface of PLLA scaffolds.
3.2 FT-IR spectroscopy
FT-IR spectroscopy was utilized as anoth-
er supporting evidence for the formulation of 
modified PLLA scaffolds and Tet-loaded PLLA 
scaffolds. FT-IR spectrograms of samples were 
given in Fig. 2. The hydroxyl (-OH), amino (-
NH2) and cyano (-CONH2) groups gelatin 
stretching bands at 3000-3700 cm–1 (as the ar-
row in the Figure 3 shown) , as well as C=O 
gelatin stretching bands at 1651 cm–1 and 
amino gelatin characteristic absorption bands 
at 1557 cm–1 appeared in the FT-IR spectro-
gram of modified PLLA scaffolds. These were 
evidence of gelatin contained on the surface of 
modified PLLA scaffolds. 
In comparison to the FT-IR spectrum of 
modified PLLA scaffolds, Tet-loaded PLLA 
scaffolds exhibits little changes in shapes, 
while the strength and width of characteristic 
absorption bands increased due to approxi-
mately the superposition of Tet and modified 
PLLA scaffolds. 
3.3 XRD
According to previous reports, modified 
PLLA scaffolds were conducive to cell adhe-
sion, proliferation and function, so it has bright 
future in tissue engineering [3,4,33]. With the 
aim to confirm the potentiality of Tet-loaded 
PLLA scaffolds in chondrocyte tissue engi-
neering, XRD was measured. XRD clearly 
confirmed the crystalline nature of Tet as 
well as the amorphous state of PLLA scaffolds 
(Figure 3). The crystalline peaks of modified 
PLLA scaffolds that at 2θ are equal to 16.6° 
and 19.1° which in accordance with the conclu-
sion previous reported by Hideto Tsuji [19].
These peaks are comparable with α form of 
PLLA crystallized in a pseudo-orthorhombic 
unit cell of dimensions: a = 1.07 nm, b = 0.595 
nm and c = 2.78 nm which contains two 103 he-
lices. It was worth noting that the shape of Tet-
loaded scaffolds observed on diffractograms 
showed no significant differences from that of 
modified PLLA scaffolds. Therefore, the load-
ing of Tet did not change the crystallinity of the 
scaffolds. 
3.4  DSC 
DSC thermograms of modified PLLA scaf-
folds and Tet-loaded PLLA scaffolds were re-
ported in Figure 4, and the melting temperature 
(Tpeak) and fusion enthalpy (ΔH) were listed in 
Table 2. As can be discovered, the thermogram of 
modified PLLA scaffolds showed a fusion endo-
Fig 1. The XPS spectrum of PLLA scaffolds (a), 
modified PLLA scaffolds (b) and Tet-loaded 
PLLA scaffolds (c).
Fig. 2. FT-IR spectrum of Tet (a), PLLA scaffolds 
(b), modified PLLA scaffolds (c) and Tet-loaded 
PLLA scaffolds (d).
Table 1. The elements composition of PLLA scaffolds (a), modified PLLA scaffolds (b) and Tet-loaded 
PLLA scaffolds (c)
Samples
element composition (%)
C O N
PLLA scaffolds 65.6 34.4 0
modified PLLA scaffolds 63.2 33.6 3.1
Tet-loaded PLLA scaffolds 63.6 32.5 3.8
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thermic peak at 153.3°C (ΔH = 44.29 J/g) corre-
spondent to its melting point. The thermogram 
of Tet-loaded scaffolds exhibits no significant 
difference in Tpeak and ΔH from that of modified 
PLLA scaffolds, which could be explained by 
the existent of Tet did not change the thermo-
dynamics of the scaffolds.
3.5 SEM
The morphologies of the scaffolds were 
shown in Figure 5. What can be found was that 
the scaffolds all acquire network structures 
constructing of ultrafine fiber. Moreover, the 
average fiber diameter and pore size of Tet-
loaded PLLA scaffolds varies little with that of 
modified PLLA scaffolds. In other words, the 
molecular structure of scaffolds keeps identical 
after Tet containing. Therefore, the loading of 
Tet did not change the morphous of the scaf-
folds. This would be helpful for Tet-loaded scaf-
folds to be used in chondrocyte tissue engineer-
ing field.
3.6  Drug release behaviors
The drug loading content was calculated 
from the ratio of amount of drug containing in 
the PLLA scaffold and the weight of PLLA scaf-
fold, and up to 0.652 mg/g. It was worth noting 
that the experimental amount of loading drug 
is much smaller than the theoretical amount. 
It may be due to considerable dissolving of Tet 
during the process of replacing THF with 50% 
(V/V) ethanol and then with distilled water. 
Therefore, it is of utmost importance to assay 
the drug loading content of Tet-loaded PLLA 
scaffolds. In addition, the Tet content has sig-
nificant influence on the behaviors of chondro-
cyte. It had been proved that low tetrandrine 
was beneficial for chondrocyte proliferation, 
chondrocyte activity and chondrocyte expres-
sion, and thus for chondrocyte tissue recon-
struction [26]. In this paper, the average drug 
Fig. 3. X-ray diffractograms of Tet (a), PLLA 
scaffolds (b) and Tet-loaded PLLA scaffolds (c).
Fig. 4. DSC thermograms of modified PLLA scaf-
folds (a) and Tet-loaded PLLA scaffolds (b).
Fig. 5. SEM photographs of modified PLLA scaffolds (left) and Tet-loaded PLLA scaffolds (right).
Table 2. Differential scanning calorimetric 
data of PLLA scaffolds
Samples Tonset, °C Tpeak, °C ΔH (J·g–1)
modified PLLA 
scaffolds 140.0 153.3 44.29
Tet-loaded 
PLLA scaffolds 139.0 152.7 49.4
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loading content of Tet-loaded PLLA scaffolds 
was about 0.652 mg/g which favorable for Tet-
loaded scaffolds using in chondrocyte tissue en-
gineering field.
The release behaviors of Tet-loaded PLLA 
scaffolds were reported in Figure 6. As can 
be discovered, the initial burst effect was not 
observed in all examined samples, which con-
firmed that Tet-loaded PLLA scaffolds could be 
prepared without any residual drug on their 
surfaces. In the initial stage, the release rate 
increased slowly. After that, the drug released 
from the scaffolds increased apparently. Tet 
loaded into the pores of PLLA scaffolds showed 
significant sustained release characteristics of 
about 79.15% in 188 days. The scaffolds keep 
good integrity through release studies.
Drug release behaviors also have important 
effect on the behaviors of chondrocyte. It is gen-
erally assumed that a drug is released by sever-
al mechanics: (a) Fickian diffusion through the 
polymer matrix, (b) diffusion through pores in 
the matrix, and (c) drug liberation by polymer 
erosion. For Tet-loaded PLLA scaffolds, Tet 
is physically entrapped in PLLA matrix. And 
the degradation of PLLA scaffolds during the 
experiment period is ignorable which reported 
in many studies [8, 19, 27, 28,]. Therefore, it 
is speculated that the drug release from the 
scaffolds is carried out mainly through Fickian 
diffusion. Although the network of PLLA scaf-
folds which is the main diffusion barrier of Tet 
can swell in water solution and that should be 
a positive factor to improve Tet diffusion, Tet is 
a lipophilic alkaloid and its solubility in water 
is very low. This will result in the decrease of 
Tet release rate.
4. Conclusions
This study explored the potential of Tet-
loaded PLLA scaffolds in cartilage tissue engi-
neering. XPS and FT-IR spectroscopy demon-
strated that Tet was contained in the scaffolds. 
DSC, SEM and XRD confirmed that Tet did not 
change the morphous, crystallinity and ther-
modynamics of the scaffolds. Release studies 
revealed that Tet was released gradually, ap-
proximately 79.15% in 188 days. In addition, 
the scaffolds keep good integrity through re-
lease studies. Therefore, Tet-loaded PLLA scaf-
folds offer a considerable potential in chondro-
cyte tissue engineering, thus broadening the 
clinical application. 
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